JILL BROADFOOT

Chief Financial Officer aTyr Pharma

Jill Broadfoot is Chief Financial Officer of aTyr Pharma (Nasdaq: LIFE), a publicly traded clinical stage biotechnology company. Broadfoot has more than 30 years of experience in accounting and finance. She raised $86.3 million via public offering in September 2021 and implemented flexible equity vehicles to support the company's financing, including a $20 million common stock purchase agreement in 2020. Prior to joining aTyr in 2018, she was CFO of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations, corporate governance, finance and accounting and investor relations functions. She previously was VP, U.S. Corporate Controller at GW Pharmaceuticals, was CFO of Vical Inc., and held various positions at DJO Global, Inc. She was an audit manager at Ernst & Young LLP and division controller for the Medical Imaging Centers of America. She serves on the board of directors for Otonomy, Inc. and AcelRx Pharmaceuticals, Inc. (ACRX).